Gilead Poised to Upend Market With Its First Covid-19 Study Data
A person enters a building at Gilead Sciences Inc. headquarters in Foster City, California, U.S. (Photographer: David Paul Morris/Bloomberg)

Gilead Poised to Upend Market With Its First Covid-19 Study Data

(Bloomberg) -- Gilead Sciences Inc., whose Covid-19 treatment has whipsawed markets amid conflicting early reports about its efficacy, is set to report the first results from a company-sponsored st...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.